INSIGHTS

A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long

Nearly half of new product launches underperform their forecasts, revealing a gap between planning and real-world market response. A successful product launch strategy requires more than data—it demands insight from customers, sales teams, and payers. By integrating these perspectives, companies can uncover hidden barriers, refine positioning, and unlock sustainable growth rooted in real-world understanding.

The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.

To thrive in today’s evolving healthcare market landscape, medical device companies must take a cohesive, strategic approach to address the complexities and opportunities of the current environment. Success will hinge on aligning commercial models with customer priorities, reducing inefficiencies, and leveraging technology to drive smarter decisions. By Jeremy Cohen, Spinnaker Life Sciences Strategy Consulting.

GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.

Strategic FP&A is vital for emerging life sciences companies facing long R&D cycles and capital constraints. By aligning financial insights with scientific priorities, FP&A enables smarter capital allocation, scenario planning, and investor confidence. Robust FP&A functions drive data-driven decisions, extend runway, and enhance operational discipline—empowering biotech and pharma leaders to balance innovation with financial sustainability and accelerate progress toward comme